Cibisatamab

Description: Cibisatamab is a T-cell bispecific antibody that acts as a T-cell splicer.Cibisatamab targets carcinoembryonic antigen (CEA) on cancer cells and CD3 on T-cells, and triggers T-cell killing when the CEA on the surface of the cancer cells ranges from intermediate to high levels.Cibisatamab may be used to study solid cancers such as colorectal cancer. Target: Others. References: Reyes Gonzalez-Exposito, et al. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. J Immunother Cancer. 2019 Apr 15,7(1):101.